FreeCME

Community Practice Connections™: Determining When and How to Integrate PCSK9 Inhibition Into Practice

CME: 1.5

May 25, 2022
/ Print / Reprints /
| Share More
/ Text Size+

Target Audience

This educational activity is directed toward internists and internal medicine subspecialists. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in lipid management will be invited to participate, as well.

Program Overview

Proprotein convertase subtilisin/kexin type 9 (PCSK9) serine protease inhibitors provide important advances in the management of dyslipidemia and cardiovascular disease risk. Clinician education about current and emerging data for this class of agents is expected to improve clinical care and patient outcomes. This activity will help clinicians to identify specific subsets of patients who may be candidates for nonstatin-based approaches, including optimized application of PCSK9 inhibitors. It will also review data concerning these agents and best practices for their clinical use.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify which patients are most likely to benefit from PCSK9 inhibition for the treatment of hypercholesterolemia.
  • Evaluate recent efficacy and safety data and for the use of PCSK9 inhibitors for cardiovascular risk reduction in patients not achieving lipid treatment goals
  • Apply treatment strategies to individual care plans for patients at cardiovascular risk needing additional lipid reduction
  • Discuss current evidence regarding access barriers for the use of PCSK9 inhibitors

Post a comment to this article